Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JKN2403 in moderate-to-severe COPD
NCT07351734Phase 2Recruiting
- Sponsor
- Joincare Pharmaceutical
- Start
- Nov 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JKN2403 in chronic obstructive pulmonary disease (COPD), sponsored by Joincare Pharmaceutical. Started Nov 2025; status: recruiting.
02
Drugs
JKN2403
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07351734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07351734.